COCRYSTAL PHARMA, INC. Marketable Securities, Unrealized Gain (Loss)
COCRYSTAL PHARMA, INC. (COCP) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2017-03-31
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2016-03-31 was $0.00.
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2015-06-30 was $744.00K, a 77.82% decline year-over-year.
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2015-03-31 was -$980.00K.
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2014-12-31 was -$2.00M.
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- COCRYSTAL PHARMA, INC. marketable securities, unrealized gain (loss) for fiscal 2014 was $236.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-03-15 | |||
| 2015-06-30 | $744.00K 10-Q · filed 2016-08-09 | -$236.00K 10-Q · filed 2016-08-09 | -$2.23M derived: sum of 3 quarters · filed 2017-03-31 | -$1.83M derived: sum of 4 quarters · filed 2017-03-31 |
| 2015-03-31 | -$980.00K 10-Q · filed 2016-05-10 | -$2.98M derived: sum of 2 quarters · filed 2017-03-31 | -$2.57M derived: sum of 3 quarters · filed 2017-03-31 | $783.00K derived: sum of 4 quarters · filed 2017-03-31 |
| 2014-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$1.59M derived: sum of 2 quarters · filed 2017-03-31 | $1.76M derived: sum of 3 quarters · filed 2017-03-31 | $236.00K 10-K · filed 2017-03-31 |
| 2014-09-30 | $408.00K 10-Q · filed 2015-11-16 | $3.76M derived: sum of 2 quarters · filed 2015-11-16 | $2.23M 10-Q · filed 2015-11-16 | |
| 2014-06-30 | $3.35M 10-Q · filed 2015-08-14 | $1.83M 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | -$1.45M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |